CVRx Inc is primarily active in the medical device industry.

The main competitors of CVRx Inc in the market include companies like Medtronic, Boston Scientific, and Abbott Laboratories. These companies operate in the medical device industry and offer products and solutions similar to CVRx Inc. Medtronic, a global leader in medical technology, develops innovative therapies for various health conditions including heart failure, where CVRx Inc primarily focuses. Boston Scientific is another significant competitor known for its medical devices and solutions, including those related to heart failure. Abbott Laboratories also competes in this space, providing advanced medical technologies and treatments. These competitors pose challenges to CVRx Inc in terms of product offering, market share, and innovation.

CVRx Inc is a medical technology company established in 2001, specializing in the development of innovative therapies for patients with chronic heart and autonomic nervous system disorders. The company's headquarters are located in Minneapolis, Minnesota, USA. CVRx Inc is renowned for its breakthrough Barostim Neo system, an implantable device that delivers Baroreflex Activation Therapy® (BAT) to help manage treatment-resistant hypertension (high blood pressure). This therapy has received approval in Europe and other international markets, allowing CVRx Inc to provide a unique solution to patients suffering from this condition. CVRx Inc has a rich history of pioneering advancements in medical technology for cardiovascular health.

CVRx Inc has achieved several significant milestones in its corporate journey. The company successfully received FDA approval for its innovative Barostim Neo System in 2019, marking a major breakthrough in the treatment of heart failure. CVRx Inc also completed a pivotal clinical trial, demonstrating substantial improvement in patients' quality of life and reduction in heart failure-related hospitalizations. In addition, CVRx Inc secured significant funding through successful financing rounds, enabling further research and development efforts. These milestones highlight the company's commitment to revolutionizing cardiovascular healthcare and position CVRx Inc as a leading player in the field.

CVRx Inc is primarily present in the United States.

CVRx Inc represents a strong commitment to improving patient outcomes and transforming the treatment of cardiovascular diseases. The company believes in innovation and aims to provide groundbreaking medical technologies. CVRx focuses on developing and commercializing the BAROSTIM NEO, a neuromodulation therapy that helps regulate the body's natural cardiovascular function. With its dedication to scientific research and cutting-edge solutions, CVRx Inc is dedicated to making a positive impact in the lives of patients suffering from conditions like heart failure and hypertension.

Analysts currently set an average price target of 11,73 USD for the CVRx stock (median: 12,24 USD), implying +126,7 % versus the latest price. The consensus is based on 13 analyst ratings.

CVRx Analyytikkojen kursstavoitteet 2026

13 analysts currently rate the CVRx stock: 11 recommend buying, 1 holding and 1 selling. For 2026, analysts expect CVRx to generate revenue of 65,33 M USD and earnings per share of −1,96 USD.

CVRx Analyytikkojen kursstavoitteet 2026

Converted at the current exchange rate, the CVRx share trades at 4,80 EUR (5,52 USD).

The CVRx share (CVRX) is listed on 1 stock exchanges, including: NASDAQ (CVRX).

CVRx Inc. is a biomedical company that develops innovative therapies for the treatment of cardiovascular diseases. The company was founded in Minneapolis in 2001 with the goal of helping patients by developing solutions that can improve quality of life and prolong life. CVRx's core business is the development of implantable medical devices that work with the patented Baroreflex Activation Therapy. The technology regulates blood pressure by stimulating the baroreflex, a vital mechanism that regulates blood pressure to a healthy level. This therapy regulates the body's cardiovascular system, leading to improved physical function and reduced medical complications. CVRx's flagship product is the Barostim Neo™ Baroreflex Activation Therapy (BAT), which is used to treat patients with severe heart failure and hypertension. The system consists of an implantable stimulator and an external programmer used by doctors to customize the therapy to each patient's specific needs. Barostim Neo™ was approved by the US Food and Drug Administration (FDA) in 2019 and has been approved in Europe since 2009. In addition to Barostim Neo™, CVRx is also working on the development of other devices and technologies for the treatment of cardiovascular diseases. This includes systems for regular monitoring of vital signs and diagnostic devices for the early detection of heart failure. CVRx is a global company with offices in North America and Europe. The company has over 150 employees, including experts in research and development, clinical trials, production, and distribution. CVRx collaborates closely with medical professionals, insurance providers, and patient organizations to ensure broad acceptance and availability of its products. The company's business operations are based on an innovative and cost-conscious approach. CVRx aims to increase access to innovative therapies while also reducing healthcare costs. Barostim Neo™ is an example of this approach and has the potential to reduce healthcare costs by decreasing medical complications and hospitalizations. In summary, CVRx is an innovative and growing company focused on the development of therapies for the treatment of cardiovascular diseases. The Barostim Neo™ is the company's flagship product and has already played a significant role in treating patients with severe heart failure and hypertension. CVRx continues to work on developing new solutions that can improve quality of life and prolong life for patients.

odotettu liikevaihto CVRx on 65,33 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto CVRx on −51,44 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

CVRx:n hinta-voitto-suhde (P/E) on tällä hetkellä −2,81. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan CVRx-osakkeen arvostusta.

CVRx:n hinta-myynti-suhde (P/S) on tällä hetkellä 2,22. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii CVRx-osakkeen arvostuskennuslukuna.

CVRx:n Eulpool-laatuscore on 3/10.

CVRx:n ISIN on US1266381052. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

CVRx:n ticker on CVRX. Tämä pörssinoteeraus käytetään CVRx-osakkeiden kauppaan pörssissä.

CVRx maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.

CVRx kuuluu sektoriin 'Terveydenhuolto'.

CVRx:n osingot jaetaan valuutassa USD.